Differences between 2023 and 2024 COVID vaccine formulations for at-risk groups
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
The principal difference between the 2023 and 2024 COVID‑19 vaccine formulations is the viral lineage each was designed to match: 2023 doses were updated to a monovalent formulation targeting the Omicron XBB lineage, whereas the 2024‑era updates shifted to newer Omicron descendants (including KP lineage subvariants) to better reflect circulating viruses and preserve protection against severe outcomes in higher‑risk people [1] [2]. Public health guidance around who should get these updated doses also evolved toward a risk‑based, individualized approach emphasizing older adults and people with underlying conditions [1] [3].
1. How the antigen changed: XBB in 2023 versus newer Omicron descendants in 2024
Regulatory and manufacturer updates in 2023 moved U.S. vaccines away from the earlier bivalent formulations and toward a monovalent vaccine that specifically targeted the XBB lineage of Omicron for the 2023–2024 season, a change intended to improve immunologic matching to the dominant strains at that time [1]. By the 2024‑era updates, manufacturers and regulators recommended formulations designed against more recent Omicron sublineages—including those in the KP/JN.1 family—reflecting viral evolution and the need for the vaccine antigen to mirror circulating variants for optimal protection against severe disease [2] [3].
2. Clinical intent: preventing severe outcomes for at‑risk groups rather than blocking all infections
Across both years the stated goal of the updated formulas was to reduce hospitalizations, critical illness and deaths rather than to eliminate transmission entirely; regulators authorized the new antigenic matches based on evidence they boost protection against severe outcomes even when infections still occur [2] [1]. Studies and advisory presentations noted that updated vaccines in subsequent seasons reduced hospitalizations and provided the best protection against critical illness in older adults, the group at highest risk [4] [5].
3. Who was prioritized: explicit eligibility and risk‑based emphasis
The 2023 monovalent authorizations placed particular emphasis on older adults and immunocompromised people as groups that benefit most from updated doses, a focus that persisted into 2024‑era guidance where clinicians and public health bodies stressed targeting people with risk factors for severe COVID‑19 such as advanced age, certain chronic conditions, pregnancy and immunosuppression [1] [5]. By 2024–2025 and into later guidance, U.S. agencies leaned more heavily on shared clinical decision‑making for younger, lower‑risk adults while maintaining clearer recommendations for older and medically vulnerable populations [3] [6].
4. Authorization nuances and pediatric considerations
Regulatory actions in 2023 included emergency use authorizations and formulation approvals that adjusted age eligibility and dosing for children, with some 2023–2024 authorizations extending Moderna’s use in younger pediatric groups and lowering age thresholds in specific cases; those pediatric authorizations were tied to the XBB‑targeted formulation available that season [7] [1]. Subsequent seasons carried forward risk‑based pediatric guidance, with professional societies and CDC materials advising a targeted approach for children based on age and underlying conditions [8] [5].
5. Practical implications and limits of the record
For clinicians and high‑risk individuals the practical implication was straightforward: get the formulation that matches the most recent guidance and consider timing before winter peaks to maximize protection against severe illness, especially for older adults and those with risk factors [5] [8]. Reporting shows clear lineage shifts between 2023 and later updates and consistent emphasis on protecting vulnerable groups, but precise comparative effectiveness head‑to‑head between the 2023 XBB monovalent shot and each subsequent 2024‑era formulation in varied risk strata remains limited in publicly released randomized data—regulators often relied on immunologic and observational evidence to authorize annual antigen updates [2] [4].